Current Edition

Precision Power Helps Drive the Drug Development Process for Speciality Medicines

Innovation is the ultimate engine of growth for the global
provision of medicines. Speed to market through faster drug
development processes is continually in demand, as the
need for speciality drugs grows. Entering Phase I clinical
trials as early as possible can be key, enabling either rapid
progress to Phase II or faster decisions on viability. Here, PCI
Pharma Services’ Dave O’Connell explains how cutting-edge
technology such as Xcelodose can be a major asset, delivering
a number of benefits to the drug development process.